{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:52:02Z","timestamp":1792266722019,"version":"4.4.0"},"reference-count":158,"publisher":"Impact Journals, LLC","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,10,11]]},"DOI":"10.18632\/oncotarget.11509","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T03:44:50Z","timestamp":1471923890000},"page":"67551-67573","source":"Crossref","is-referenced-by-count":44,"title":["Pediatric Hodgkin lymphoma- biomarkers, drugs, and clinical trials for translational science and medicine"],"prefix":"10.18632","volume":"7","author":[{"given":"Poonam","family":"Nagpal","sequence":"first","affiliation":[{"name":"The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Akl","sequence":"additional","affiliation":[{"name":"The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehad M.","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunari","family":"Tomiyama","sequence":"additional","affiliation":[{"name":"The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasheka","family":"Cousins","sequence":"additional","affiliation":[{"name":"The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Tai","sequence":"additional","affiliation":[{"name":"The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Carroll","sequence":"additional","affiliation":[{"name":"The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themba","family":"Nyrenda","sequence":"additional","affiliation":[{"name":"Department of Research, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritish","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"Clinical Divisions, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pecora","sequence":"additional","affiliation":[{"name":"Clinical Divisions, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Stephen","family":"Suh","sequence":"additional","affiliation":[{"name":"The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"},{"name":"Department of Research, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"Hansmann","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2","first-page":"1644","article-title":"Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma","volume":"63","author":"Hansmann","year":"2003","journal-title":"Cancer Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","author":"Rajewsky","year":"1996","journal-title":"The Journal of experimental medicine"},{"issue":"Suppl 1","key":"4","first-page":"11","article-title":"Biology of Hodgkin's lymphoma","volume":"13","author":"Hansmann","year":"2002","journal-title":"Ann Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Kuppers","year":"2003","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V97.2.496","article-title":"Down-regulation of BOB.1\/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription","volume":"97","author":"Falini","year":"2001","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.MP.0000093627.51090.3F","article-title":"Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases","volume":"16","author":"Dirnhofer","year":"2003","journal-title":"Mod Pathol"},{"key":"8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.191.2.387","article-title":"Rare occurrence of classical Hodgkin's disease as a T cell lymphoma","volume":"191","author":"Kuppers","year":"2000","journal-title":"The Journal of experimental medicine"},{"key":"9","first-page":"543","article-title":"Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease","volume":"150","author":"Said","year":"1997","journal-title":"Evidence for a dendritic or B cell derivation? The American journal of pathology"},{"key":"10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/modpathol.3800473","article-title":"Rare expression of T-cell markers in classical Hodgkin's lymphoma","volume":"18","author":"Dirnhofer","year":"2005","journal-title":"Mod Pathol"},{"key":"11","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2012-06-439455","article-title":"Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival","volume":"121","author":"Jaffe","year":"2013","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/asheducation-2009.1.491","article-title":"Molecular biology of Hodgkin lymphoma","author":"K\u00fcppers","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"13","volume-title":"SEER Cancer Statistics Review","author":"Chen","year":"1975"},{"key":"14","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2005.04.5823","article-title":"Hodgkin's lymphoma in adolescents","volume":"24","author":"Connors","year":"2006","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.mehy.2006.11.014","article-title":"Bimodal age distribution in Hodgkin's disease and nasopharyngeal carcinoma","volume":"68","author":"Ozyar","year":"2007","journal-title":"Med Hypotheses"},{"key":"16","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3109\/10428194.2010.525724","article-title":"Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases","volume":"51","author":"Sultan","year":"2010","journal-title":"Leukemia & lymphoma"},{"key":"17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1008337100424","article-title":"Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells","volume":"11","author":"Bhatia","year":"2000","journal-title":"Ann Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","article-title":"Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor","volume":"17","author":"Hammerschmidt","year":"1998","journal-title":"EMBO J"},{"key":"19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals","volume":"9","author":"Longnecker","year":"1998","journal-title":"Immunity"},{"key":"20","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.bjc.6690827","article-title":"Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function","volume":"81","author":"Bjorkholm","year":"1999","journal-title":"Br J Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM198902233200806","article-title":"Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease","volume":"320","author":"Sklar","year":"1989","journal-title":"N Engl J Med"},{"key":"22","article-title":"Analysis of NF- B pathway proteins in pediatric Hodgkin lymphoma: Correlations with EBV status and clinical outcome - A Children's Oncology Group study","volume":"2012","author":"Liu","year":"2012","journal-title":"Lymphoma"},{"key":"23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"K\u00fcppers","year":"2009","journal-title":"The Journal of experimental medicine"},{"key":"24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/lrb.2007.5305","article-title":"Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr virus positive and negative pediatric Hodgkin lymphoma","volume":"5","author":"Vergin","year":"2007","journal-title":"Lymphat Res Biol"},{"key":"25","first-page":"283","article-title":"EBV in pediatric neoplasia\u2014intensity of infection as independent prognostic factor","volume":"5","author":"Cainap","year":"2012","journal-title":"Journal of medicine and life"},{"key":"26","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.2005.01.701","article-title":"Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma","volume":"23","author":"D\u00f6rffel","year":"2005","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MPH.0b013e3181647bc3","article-title":"Pediatric Hodgkin lymphoma in 2 South American series: a distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome","volume":"30","author":"Preciado","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/jcp.53.3.182","article-title":"Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases","volume":"53","author":"Sinclair-Smith","year":"2000","journal-title":"J Clin Pathol"},{"key":"29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.arcmed.2014.06.001","article-title":"Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis","volume":"45","author":"Kim","year":"2014","journal-title":"Arch Med Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ijc.2910480103","article-title":"Community lifestyle characteristics and incidence of Hodgkin's disease in young people","volume":"48","author":"Cartwright","year":"1991","journal-title":"Int J Cancer"},{"key":"31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/aje\/kws212","article-title":"Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood","volume":"176","author":"Sundquist","year":"2012","journal-title":"Am J Epidemiol"},{"key":"32","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1182\/blood-2015-04-639781","article-title":"Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries","volume":"126","author":"Hemminki","year":"2015","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1056\/NEJM199502163320701","article-title":"Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease","volume":"332","author":"Rappaport","year":"1995","journal-title":"N Engl J Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2015-04-537498","article-title":"Familial predisposition and genetic risk factors for lymphoma","volume":"126","author":"Slager","year":"2015","journal-title":"Blood"},{"key":"35","first-page":"29","article-title":"Predictors of early response and event-free survival in Hodgkin lymphoma (HL): PET versus CT imaging","author":"Chen","year":"2011","journal-title":"Journal of Clinical Oncology Conference: ASCO Annual Meeting"},{"key":"36","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3109\/10428194.2010.489243","article-title":"Cell cycle characteristics and Epstein-Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients","volume":"51","author":"Hassan","year":"2010","journal-title":"Leukemia & lymphoma"},{"key":"37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/01.mph.0000212955.43350.bb","article-title":"No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas","volume":"28","author":"Preciado","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF01715132","article-title":"The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood","volume":"68","author":"Parwaresch","year":"1994","journal-title":"Ann Hematol"},{"key":"39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ajcp\/90.6.670","article-title":"Prognostic value of DNA ploidy and proliferative activity in Hodgkin's disease","volume":"90","author":"Korkeila","year":"1988","journal-title":"Am J Clin Pathol"},{"key":"40","first-page":"2429","article-title":"Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression","volume":"90","author":"Montalban","year":"1997","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/modpathol.3800466","article-title":"Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase","volume":"18","author":"Parwaresch","year":"2005","journal-title":"Mod Pathol"},{"key":"42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/pbc.21380","article-title":"Prognostic impact of CD15 expression and proliferative index in the outcome of children with classical Hodgkin lymphoma","volume":"50","author":"Hassan","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/pbc.21204","article-title":"Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma","volume":"50","author":"Dawar","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.clinbiochem.2009.04.004","article-title":"Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias","volume":"42","author":"Stepinski","year":"2009","journal-title":"Clin Biochem"},{"key":"45","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/sj.onc.1205337","article-title":"Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells","volume":"21","author":"Kadin","year":"2002","journal-title":"Oncogene"},{"key":"46","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1016\/j.ejca.2013.05.024","article-title":"The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma","volume":"49","author":"Chung","year":"2013","journal-title":"Eur J Cancer"},{"key":"47","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood.V91.8.3011.3011_3011_3016","article-title":"Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome","volume":"91","author":"Pizzolo","year":"1998","journal-title":"Blood"},{"key":"48","first-page":"4","article-title":"Role of integrins and other cell adhesion molecules in tumor progression and metastasis","volume":"68","author":"Albelda","year":"1993","journal-title":"Lab Invest"},{"key":"49","first-page":"1337","article-title":"Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease","volume":"140","author":"Baroni","year":"1992","journal-title":"The American journal of pathology"},{"key":"50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/088800199277470","article-title":"Serum levels and differential expression of intercellular adhesion molecule-1 in childhood leukemia and malignant lymphoma: prognostic importance and relationship with survival","volume":"16","author":"Okcuoglu-Cavdar","year":"1999","journal-title":"Pediatr Hematol Oncol"},{"key":"51","first-page":"1242","article-title":"Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood","volume":"7","author":"Crist","year":"1993","journal-title":"Leukemia"},{"key":"52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000117798","article-title":"Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma","volume":"17","author":"Abbas","year":"2008","journal-title":"Med Princ Pract"},{"key":"53","first-page":"534","article-title":"Serum osteopontin and CD44 levels in lymphoreticular malignancies in children","volume":"113","author":"Acar","year":"2012","journal-title":"Bratisl Lek Listy"},{"key":"54","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1442-200X.2001.01415.x","article-title":"Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival","volume":"43","author":"Cin","year":"2001","journal-title":"Pediatr Int"},{"key":"55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1470-2045(04)01414-7","article-title":"Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression","volume":"5","author":"Yang","year":"2004","journal-title":"Lancet Oncol"},{"key":"56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/pbc.21581","article-title":"Serum protein expression profiling in pediatric Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"51","author":"Semmes","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"57","first-page":"249","article-title":"Prognostic role of natural killer cells in pediatric mixed cellularity and nodular sclerosing Hodgkin's disease","volume":"24","author":"Vergin","year":"2002","journal-title":"Anal Quant Cytol Histol"},{"key":"58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/088800100276488","article-title":"Natural killer cell numbers and cytotoxic activity in pediatric Hodgkin disease","volume":"17","author":"Cavdar","year":"2000","journal-title":"Pediatr Hematol Oncol"},{"key":"59","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.it.2008.07.003","article-title":"New insights into NF-kappaB regulation and function","volume":"29","author":"Ley","year":"2008","journal-title":"Trends Immunol"},{"key":"60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","article-title":"The noncanonical NF-kappaB pathway","volume":"246","author":"Sun","year":"2012","journal-title":"Immunol Rev"},{"key":"61","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1582-4934.2004.tb00469.x","article-title":"Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury","volume":"8","author":"Yin","year":"2004","journal-title":"J Cell Mol Med"},{"key":"62","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Ruland","year":"2007","journal-title":"Blood"},{"key":"63","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1182\/blood.V87.10.4340.bloodjournal87104340","article-title":"High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin\/Reed-Sternberg cells","volume":"87","author":"D\u00f6rken","year":"1996","journal-title":"Blood"},{"key":"64","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V94.9.3129","article-title":"Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells","volume":"94","author":"D\u00f6rken","year":"1999","journal-title":"Blood"},{"key":"65","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.13388","article-title":"A phase 2 study of bortezomib in combination with ifosfamide\/vinorelbine in paediatric patients and young adults with refractory\/recurrent Hodgkin lymphoma: a Children's Oncology Group study","volume":"170","author":"Liu","year":"2015","journal-title":"Br J Haematol"},{"key":"66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/08880010902754917","article-title":"Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study","volume":"26","author":"Ilan","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"67","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1593\/neo.07673","article-title":"Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment","volume":"9","author":"Arush","year":"2007","journal-title":"Neoplasia"},{"key":"68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/clinchem\/47.4.617","article-title":"Pitfalls in the measurement of circulating vascular endothelial growth factor","volume":"47","author":"Jelkmann","year":"2001","journal-title":"Clin Chem"},{"key":"69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/08880010601052381","article-title":"Serum VEGF as a significant marker of treatment response in hodgkin lymphoma","volume":"24","author":"Livne","year":"2007","journal-title":"Pediatr Hematol Oncol"},{"key":"70","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/pbc.22179","article-title":"Prognostic value of proangiogenic cytokines in children with lymphomas","volume":"53","author":"Zahorska-Markiewicz","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"71","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2014-05-576140","article-title":"Reed-Sternberg cell-derived lymphotoxin- activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma","volume":"124","author":"Lim","year":"2014","journal-title":"Blood"},{"key":"72","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-12-0129","article-title":"Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact","volume":"18","author":"Niedobitek","year":"2012","journal-title":"Clinical cancer research"},{"key":"73","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Delabie","year":"2010","journal-title":"N Engl J Med"},{"key":"74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/08880018.2014.954071","article-title":"Pediatric Hodgkin lymphoma in a South Indian regional cancer center: its immunomorphology, tumor-associated macrophages, and association with Epstein-Barr virus","volume":"32","author":"Rao","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"75","doi-asserted-by":"crossref","first-page":"e0124531","DOI":"10.1371\/journal.pone.0124531","article-title":"Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival","volume":"10","author":"Niedobitek","year":"2015","journal-title":"PLoS One"},{"key":"76","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.bbmt.2014.08.016","article-title":"Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma","volume":"20","author":"Corradini","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"77","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma","volume":"97","author":"van Imhoff","year":"2012","journal-title":"Haematologica"},{"key":"78","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Gandhi","year":"2013","journal-title":"Clinical cancer research"},{"key":"79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1309\/PNVQ0PQGXHVY6L7G","article-title":"HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases","volume":"121","author":"Abbondanzo","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2559.2000.00830.x","article-title":"Varied B-cell immunophenotypes of Hodgkin\/Reed-Sternberg cells in classic Hodgkin's disease","volume":"36","author":"Mori","year":"2000","journal-title":"Histopathology"},{"key":"81","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1756-8722-6-62","article-title":"Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+\/CD30+ cells in poor outcome Hodgkin lymphoma patients","volume":"6","author":"Suh","year":"2013","journal-title":"J Hematol Oncol"},{"key":"82","first-page":"4743","article-title":"Serum levels of soluble syndecan-1 in Hodgkin's lymphoma","volume":"25","author":"Pangalis","year":"2005","journal-title":"Anticancer Res"},{"key":"83","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1600-0609.2009.01288.x","article-title":"Genetic variants in immunoregulatory genes and risk for childhood lymphomas","volume":"83","author":"Petridou","year":"2009","journal-title":"Eur J Haematol"},{"key":"84","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.4049\/jimmunol.164.7.3480","article-title":"Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production","volume":"164","author":"Lab\u00e9ta","year":"2000","journal-title":"J Immunol"},{"key":"85","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1165\/ajrcmb.20.5.3494","article-title":"A Polymorphism* in the 5\u2032 flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E","volume":"20","author":"Martinez","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"86","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2007-08-106872","article-title":"Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma","volume":"111","author":"Mack","year":"2008","journal-title":"Blood"},{"key":"87","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3324\/haematol.2010.033910","article-title":"IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach","volume":"96","author":"Resnick","year":"2011","journal-title":"Haematologica"},{"key":"88","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MPH.0000000000000366","article-title":"Atypical Clinical Course in Pediatric Hodgkin Lymphoma: Association With Germline Mutations in Interleukin-2-inducible T-Cell Kinase","volume":"37","author":"Kelly","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"89","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nm.2407","article-title":"Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma","volume":"17","author":"Cozen","year":"2011","journal-title":"Nat Med"},{"key":"90","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12253-013-9724-z","article-title":"Hodgkin disease therapy induced second malignancy susceptibility 6q21 functional variants in roma and hungarian population samples","volume":"20","author":"Melegh","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"91","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/cncr.20520","article-title":"XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease","volume":"101","author":"Davies","year":"2004","journal-title":"Cancer"},{"key":"92","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/pbc.20546","article-title":"Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study","volume":"46","author":"Chauvenet","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"93","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Klapper","year":"2010","journal-title":"J Clin Oncol"},{"key":"94","first-page":"2609","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Link","year":"2012","journal-title":"JAMA"},{"key":"95","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","author":"Hudson","year":"2011","journal-title":"Blood"},{"key":"96","first-page":"977","article-title":"Complications of treatment of Hodgkin's disease in children","volume":"66","author":"Kaplan","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"97","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O","article-title":"An evaluation of long-term survival and treatment complications in children with Hodgkin's disease","volume":"51","author":"Cassady","year":"1983","journal-title":"Cancer"},{"key":"98","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","article-title":"Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95","volume":"31","author":"Schellong","year":"2013","journal-title":"J Clin Oncol"},{"key":"99","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma\u2014a report from the Children's Oncology Group","volume":"30","author":"Nachman","year":"2012","journal-title":"J Clin Oncol"},{"key":"100","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Chauvenet","year":"2009","journal-title":"Blood"},{"key":"101","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Ganser","year":"2010","journal-title":"N Engl J Med"},{"key":"102","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Schwartz","year":"2014","journal-title":"J Clin Oncol"},{"key":"103","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"Link","year":"2010","journal-title":"J Clin Oncol"},{"key":"104","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2004.02.139","article-title":"Risk-adapted, combined-modality therapy with VAMP\/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease","volume":"22","author":"Rai","year":"2004","journal-title":"J Clin Oncol"},{"key":"105","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2010-05-285379","article-title":"BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"117","author":"Weiner","year":"2011","journal-title":"Blood"},{"key":"106","doi-asserted-by":"crossref","unstructured":"Casasnovas, Brice, Bouabdallah, Salles, Stamatoullas, Dupuis, Reman. 2015. Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study. 57th ASH Annual Meeting. Orlando, FL.","DOI":"10.1182\/blood.V126.23.577.577"},{"key":"107","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease","volume":"25","author":"Schwartz","year":"2007","journal-title":"J Clin Oncol"},{"key":"108","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbmt.2010.07.002","article-title":"Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962","volume":"17","author":"Cairo","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"109","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group","volume":"23","author":"R\u00fchl","year":"2005","journal-title":"J Clin Oncol"},{"key":"110","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1002\/cncr.25225","article-title":"Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients","volume":"116","author":"Howard","year":"2010","journal-title":"Cancer"},{"key":"111","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00277-003-0814-y","article-title":"Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease","volume":"83","author":"Schmitz","year":"2004","journal-title":"Ann Hematol"},{"key":"112","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1658-3876(09)50038-6","article-title":"Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma","volume":"2","author":"Sabbah","year":"2009","journal-title":"Hematology\/oncology and stem cell therapy"},{"key":"113","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.2012.09199.x","article-title":"Outcome of children and adolescents with recurrent\/refractory classical Hodgkin lymphoma, a study from the Soci\u00e9t\u00e9 Fran\u00e7aise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE)","volume":"158","author":"Michel","year":"2012","journal-title":"Br J Haematol"},{"key":"114","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1200\/JCO.2004.02.121","article-title":"High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices","volume":"22","author":"Agarwal","year":"2004","journal-title":"J Clin Oncol"},{"key":"115","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/leu.2014.194","article-title":"Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma","volume":"29","author":"Cairo","year":"2015","journal-title":"Leukemia"},{"key":"116","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Hudson","year":"1993","journal-title":"Lancet"},{"key":"117","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"O'Brien","year":"2001","journal-title":"Blood"},{"key":"118","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pbc.25205","article-title":"Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory\/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report","volume":"62","author":"de Alarcon","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"119","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","article-title":"Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report","volume":"27","author":"Trippett","year":"2009","journal-title":"J Clin Oncol"},{"key":"120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.hoc.2013.10.004","article-title":"Customized targeted therapy in Hodgkin lymphoma: hype or hope?","volume":"28","author":"Advani","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"121","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Wahl","year":"2003","journal-title":"Blood"},{"key":"122","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Ansell","year":"2013","journal-title":"Lancet Oncol"},{"key":"123","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Sievers","year":"2015","journal-title":"Lancet"},{"key":"124","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/138161211796197124","article-title":"The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib","volume":"17","author":"Dvorak","year":"2011","journal-title":"Curr Pharm Des"},{"key":"125","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/annonc\/mdn365","article-title":"Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma","volume":"19","author":"Friedberg","year":"2008","journal-title":"Ann Oncol"},{"key":"126","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2005-01-0427","article-title":"The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis","volume":"106","author":"Pogge von Strandmann","year":"2005","journal-title":"Blood"},{"key":"127","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","article-title":"Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines","volume":"112","author":"Younes","year":"2008","journal-title":"Blood"},{"key":"128","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1038\/bcj.2014.58","article-title":"Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression","volume":"4","author":"Younes","year":"2014","journal-title":"Blood Cancer J"},{"key":"129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10428194.2011.608448","article-title":"A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517","volume":"53","author":"Fisher","year":"2012","journal-title":"Leukemia & lymphoma"},{"key":"130","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Engert","year":"2012","journal-title":"J Clin Oncol"},{"key":"131","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","article-title":"The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis","volume":"23","author":"Zhao","year":"2009","journal-title":"Leukemia"},{"key":"132","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1158\/1078-0432.CCR-14-1829","article-title":"A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors","volume":"21","author":"Carvajal","year":"2015","journal-title":"Clinical cancer research"},{"key":"133","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.febslet.2005.03.071","article-title":"Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium","volume":"579","author":"Isacke","year":"2005","journal-title":"FEBS Lett"},{"key":"134","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1158\/1078-0432.CCR-08-0499","article-title":"Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma","volume":"14","author":"Horten","year":"2008","journal-title":"Clinical cancer research"},{"key":"135","doi-asserted-by":"publisher","first-page":"25429","DOI":"10.18632\/oncotarget.4559","article-title":"Targeting endosialin\/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"136","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Kim","year":"2015","journal-title":"N Engl J Med"},{"key":"137","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semradonc.2009.09.002","article-title":"Secondary malignancies across the age spectrum","volume":"20","author":"Travis","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"138","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2012.09211.x","article-title":"Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults","volume":"158","author":"Ma","year":"2012","journal-title":"Br J Haematol"},{"key":"139","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1200\/JCO.2003.11.059","article-title":"High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group","volume":"21","author":"Group","year":"2003","journal-title":"J Clin Oncol"},{"key":"140","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1200\/JCO.2000.18.12.2435","article-title":"Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence","volume":"18","author":"Travis","year":"2000","journal-title":"J Clin Oncol"},{"key":"141","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jnci\/93.8.618","article-title":"Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study","volume":"93","author":"Robison","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"142","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin Oncol"},{"key":"143","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.V78.4.1147.1147","article-title":"Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II","volume":"78","author":"Philip","year":"1991","journal-title":"Blood"},{"key":"144","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-2004-832340","article-title":"Late effects after therapy of Hodgkin's disease: update 2003\/04 on overwhelming post-splenectomy infections and secondary malignancies","volume":"216","author":"Riepenhausen","year":"2004","journal-title":"Klin Padiatr"},{"key":"145","first-page":"320","article-title":"Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence","volume":"112","author":"Schellong","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"146","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","article-title":"New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors","volume":"21","author":"Robison","year":"2003","journal-title":"J Clin Oncol"},{"key":"147","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.V100.2.427","article-title":"Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation","volume":"100","author":"Woods","year":"2002","journal-title":"Blood"},{"key":"148","first-page":"1427","article-title":"Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma","volume":"18","author":"Santucci","year":"2007","journal-title":"Oncol Rep"},{"key":"149","volume-title":"Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995","author":"Bunin","year":"1999"},{"key":"150","volume-title":"PDQ Cancer Information Summaries","author":"Board","year":"2002"},{"key":"151","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.leu.2401097","article-title":"Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis","volume":"12","author":"Jarrett","year":"1998","journal-title":"Leukemia"},{"key":"152","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pbc.24279","article-title":"Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group","volume":"59","author":"Chauvenet","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"153","first-page":"4378","article-title":"Phase 1\/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R\/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg\/Kg In The HL Study","author":"Mauz-Koerholz","year":"2013","journal-title":"Arm Blood"},{"key":"154","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijrobp.2008.04.067","article-title":"Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose","volume":"72","author":"Mendenhall","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"155","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2000.18.7.1492","article-title":"Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence","volume":"18","author":"Zevon","year":"2000","journal-title":"J Clin Oncol"},{"key":"156","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.1998.16.1.391","article-title":"Second cancers following pediatric Hodgkin's disease","volume":"16","author":"Donaldson","year":"1998","journal-title":"J Clin Oncol"},{"key":"157","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199603213341201","article-title":"Breast cancer and other second neoplasms after childhood Hodgkin's disease","volume":"334","author":"Meadows","year":"1996","journal-title":"N Engl J Med"},{"key":"158","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.1996.14.5.1442","article-title":"Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology","volume":"14","author":"Tulinius","year":"1996","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:41:18Z","timestamp":1718757678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":158,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2016,10,11]]}},"alternative-id":["11509","27563824"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11509","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,22]]}}}